



May 12, 2017

The Honorable Susan Collins  
United States Senate  
413 Dirksen Senate Office Building  
Washington, DC 20510

The Honorable Claire McCaskill  
United States Senate  
506 Hart Senate Office Building  
Washington DC 20510

**Re: HSCA Support for S.1115, the “Making Pharmaceutical Markets More Competitive Act”**

On behalf of the Healthcare Supply Chain Association (HSCA), thank you for your efforts to reduce healthcare costs and for working to safeguard patient and provider access to generic drugs. HSCA is pleased to support your recent legislation, the “Making Pharmaceutical Markets More Competitive Act” (S.1115). As Congress works to address generic drug price spikes, we applaud your leadership on this issue and your continued commitment to finding legislative solutions.

HSCA represents leading healthcare group purchasing organizations (GPOs), the sourcing and purchasing partners to virtually all of America’s 7,700+ hospitals, as well as the vast majority of the 68,000+ long-term care facilities, surgery centers, clinics, and other healthcare providers. GPOs deliver critical cost savings that allow healthcare providers to focus on their core mission: providing first-class patient care.

Patients have long relied on generic drugs to increase access to and reduce the costs of essential medications. HSCA commends the goal of the legislation to create a more competitive generic drug marketplace by giving priority review to abbreviated new drug applications (ANDAs) with not more than three approved drug alternatives. This will help streamline the process of additional manufacturers entering the generic market and mitigate the challenges patients and providers experience when these products face a price spike. Furthermore, HSCA appreciates your successful efforts to incorporate these vital changes into the Food and Drug Administration (FDA) user fee reauthorization process as well.

HSCA also applauds the bill’s emphasis on reporting information. Ensuring that complete and accurate information is shared between the FDA and manufacturers regarding the testing of products will be value added for supply chain managers in today’s information-driven healthcare delivery system. This helps ensure cross-disciplinary review of the application where appropriate and, ultimately, helps both parties reach a successful outcome in a timely manner.

As you consider future legislative opportunities, we look forward to continuing to collaborate on this

**HSCA MEMBER COMPANIES**





critical issue. Given our unique line of sight into all aspects of the healthcare supply chain, we would be pleased to serve as a resource to you and your staff.

Please do not hesitate to contact me directly should you have any questions. I can be reached at (202) 629-5833 or [tebert@supplychainassociation.org](mailto:tebert@supplychainassociation.org).

Sincerely,

Todd Ebert, R.Ph.  
President and CEO  
Healthcare Supply Chain Association

HSCA MEMBER COMPANIES

